CN109331113A - 辅助治疗宠物糖尿病的处方膏及其制备方法 - Google Patents
辅助治疗宠物糖尿病的处方膏及其制备方法 Download PDFInfo
- Publication number
- CN109331113A CN109331113A CN201811107961.7A CN201811107961A CN109331113A CN 109331113 A CN109331113 A CN 109331113A CN 201811107961 A CN201811107961 A CN 201811107961A CN 109331113 A CN109331113 A CN 109331113A
- Authority
- CN
- China
- Prior art keywords
- extract
- cream
- vitamin
- pet
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 42
- 239000006071 cream Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 101
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 24
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 23
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 18
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 18
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims abstract description 17
- 244000068988 Glycine max Species 0.000 claims abstract description 17
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 17
- 238000003756 stirring Methods 0.000 claims abstract description 17
- 241000605447 Anemarrhena Species 0.000 claims abstract description 16
- 229930191283 anemarrhena Natural products 0.000 claims abstract description 16
- 229940107666 astragalus root Drugs 0.000 claims abstract description 16
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 16
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 16
- 241000287828 Gallus gallus Species 0.000 claims abstract description 15
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 15
- 239000005862 Whey Substances 0.000 claims abstract description 15
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 15
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 15
- 229940046374 chromium picolinate Drugs 0.000 claims abstract description 15
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000835 fiber Substances 0.000 claims abstract description 15
- 235000021323 fish oil Nutrition 0.000 claims abstract description 15
- 235000012054 meals Nutrition 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 15
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 15
- 241000219925 Oenothera Species 0.000 claims abstract description 14
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 14
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 14
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 14
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 12
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 12
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 12
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 12
- 229940088594 vitamin Drugs 0.000 claims abstract description 12
- 229930003231 vitamin Natural products 0.000 claims abstract description 12
- 239000011782 vitamin Substances 0.000 claims abstract description 12
- 235000013343 vitamin Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 9
- 235000013330 chicken meat Nutrition 0.000 claims abstract description 8
- 239000004615 ingredient Substances 0.000 claims abstract description 8
- 229960003885 sodium benzoate Drugs 0.000 claims abstract description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000009098 adjuvant therapy Methods 0.000 claims description 13
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 239000011715 vitamin B12 Substances 0.000 claims description 9
- 239000011647 vitamin D3 Substances 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 8
- 239000011691 vitamin B1 Substances 0.000 claims description 8
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 238000000265 homogenisation Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 150000008545 L-lysines Chemical class 0.000 claims 1
- 235000014103 egg white Nutrition 0.000 claims 1
- 210000000969 egg white Anatomy 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 208000002249 Diabetes Complications Diseases 0.000 abstract description 3
- 206010012655 Diabetic complications Diseases 0.000 abstract description 3
- 239000008103 glucose Substances 0.000 description 31
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- 239000008280 blood Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 201000001421 hyperglycemia Diseases 0.000 description 11
- 230000002218 hypoglycaemic effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- 240000000249 Morus alba Species 0.000 description 4
- 235000008708 Morus alba Nutrition 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- -1 can increase female Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/22—Compounds of alkali metals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种辅助治疗宠物糖尿病的处方膏,包括以下原料组分:黄芪提取物、白术提取物、葛根提取物、知母提取物、川芎提取物、桑叶提取物、女贞子提取物、羧甲基纤维素钠、月见草籽油、鱼油、鸡肉粉、牛水解膏、分离乳清蛋白、血红素蛋白粉、大豆纤维、菊糖、果寡糖、L‑肉碱酒石酸盐、L‑赖氨酸盐酸盐、葡萄糖酸锌、吡啶甲酸铬和苯甲酸钠,采用中药与营养素结合可辅助治疗宠物糖尿病和预防宠物糖尿病并发症。本发明还公开了一种辅助治疗宠物糖尿病的处方膏的制备方法,将大部分原料先进行加热搅拌均匀,再将维生素加入进行加热,使得后集中成分不易加热太久被破坏掉,制备方法简单,便于操作。
Description
技术领域
本发明涉及宠物用营养品技术领域,特别涉及辅助治疗宠物糖尿病的处方膏及其制备方法。
背景技术
近几年来,随着我国居民生活水平的持续提高和家庭规模的缩小,宠物已经成为越来越多都市人生活和情感的一部分,而宠物扮演的角色也逐渐由满足宠主们看家的需要,逐渐转向填补宠主们情感、心理上空缺的需要,这种趋势对宠物们的生活也产生了直接的影响。很多宠物的饮食结构和生活习惯都在偏离正常的轨迹,如宠物犬猫被宠主过度饲喂、长期被饲喂能量高的饲粮、正餐之外补食多种零食、日常活动量严重不足、绝育手术等,这种情况下容易导致宠物犬猫处于超重甚至肥胖的状态,而肥胖则会容易导致犬猫患上糖尿病。
目前在宠物市场上,治疗宠物糖尿病的都是直接注射胰岛素增加机体胰岛素浓度,采用能够促进胰岛素分泌或者增加胰岛素敏感性的药物治疗。但通过胰岛素治疗宠物糖尿病一般会产生多种并发症,例如低血糖症,应激性高糖血症,临床症状的复发或持续存在、胰岛素剂量不足、胰岛素过量和血糖正向调节、胰岛素持效时间过短、胰岛素的持效时间过长、胰岛素吸收不充分或吸收不良等,严重影响了宠物的健康。为避免采用胰岛素治疗宠物糖尿病以及随之产生的多种并发症,采用中药制剂或是治疗宠物糖尿病的更佳选择,但单纯用中药并不能满足犬猫在患有糖尿病期间的营养需要,如果中药与营养素(如维生素,矿物质等)相互配合,能达到更好的效果。且目前市场上尚未出现一款产品是结合植物草本精华和营养素来改善患宠物体内糖脂代谢,改善高血糖和高血脂应激对机体的损害的功能型营养品。
发明内容
根据本发明的一个方面,提供了一种辅助治疗宠物糖尿病的处方膏可以解决上述问题的一个或者多个,本发明的辅助治疗宠物糖尿病的处方膏包括以下原料组分:黄芪提取物、白术提取物、葛根提取物、知母提取物、川芎提取物、桑叶提取物、女贞子提取物、羧甲基纤维素钠、月见草籽油、鱼油、鸡肉粉、牛水解膏、分离乳清蛋白、血红素蛋白粉、大豆纤维、菊糖、果寡糖、L-肉碱酒石酸盐、L-赖氨酸盐酸盐、葡萄糖酸锌、吡啶甲酸铬和苯甲酸钠。
其中,辅助治疗宠物糖尿病的处方膏还包括维生素。
其中,维生素包括维生素B1、维生素B12、维生素D3和维生素E中的一种或多种。
进一步的,辅助治疗宠物糖尿病的处方膏包括以下质量百分数含量的原料组分:黄芪提取物:0.5%-1.5%、白术提取物:0.5%-1.5%、葛根提取物:1.5%-2.5%、知母提取物:1%-2%、川芎提取物:0.5%-1.5%、桑叶提取物:0.5%-1.5%、女贞子提取物:0.5%-1.5%、羧甲基纤维素钠:0.5%-1%、月见草籽油:2%-10%、鱼油:2%-10%、鸡肉粉:5%-15%、牛水解膏:1%-8%、分离乳清蛋白:1%-5%、血红素蛋白粉:0.5%-5%、大豆纤维:0.5%-6%、菊糖:0.5%-6%、果寡糖:1%-6%、L-肉碱酒石酸盐:0.2%-1%、L-赖氨酸盐酸盐:0.25%、维生素B1:0.022%、维生素B12:0.005%、维生素D3:0.008%、维生素E:0.015%、葡萄糖酸锌:0.6%、吡啶甲酸铬:0.0001%、苯甲酸钠:0.25%,余量由水补足。
更进一步的,优选原料配方及其质量百分数含量为:黄芪提取物:1%、白术提取物:1%、葛根提取物:2%、知母提取物:1.5%、川芎提取物:1%、桑叶提取物:1%、女贞子提取物:1%、羧甲基纤维素钠:0.75%、月见草籽油:6%、鱼油:6%、鸡肉粉:10%、牛水解膏:4.5%、分离乳清蛋白:2.5%、血红素蛋白粉:3%、大豆纤维:3.5%、菊糖:3%、果寡糖:3%、L-肉碱酒石酸盐:0.65%和L-赖氨酸盐酸盐:0.25%。
其中,各原料有益效果如下:
黄芪提取物:黄芪中的多糖、黄酮、皂苷等多种活性成分,尤其是黄芪多糖,能够有效调节机体免疫功能,改善胰岛素抵抗,对糖尿病及其并发症的综合防治已显示良好的应用前景。
白术提取物:相关实验证明,白术中的白术多糖能降低血浆胰岛素水平,增加胰岛素敏感性指数,改善糖耐量,其降糖作用机制之一可能是通过降低血浆胰岛素、增加胰岛素的敏感性。
葛根提取物:葛根主要含有葛根素和大豆甘等成分,具有解热、降血糖作用,改善高血糖动物的糖耐量,增加胰岛素敏感性。葛根素尚有降血脂作用。
知母提取物:知母主要含皂苷类成分,具有抑制交感神经的升血糖作用,对高糖应激状态对机体血管、心肌和动脉的损伤有辅助保护作用。
川芎提取物:川芎对肾脏和肝脏有保护作用,川芎嗪对糖尿病肾病有保护作用,对各种原因造成的肝损伤均有保护作用。
桑叶提取物:桑叶中含有的1-脱氧野尻毒素(DNJ)是α-糖苷酶的强烈抑制剂,能够阻碍蔗糖和麦芽糖的水解,进而减少葡萄糖的吸收,降低餐后血糖峰值。桑叶黄酮和桑叶多糖也有一定促进胰岛素分泌和辅助降血糖作用,能够改善糖尿病小鼠症状。同时桑叶黄酮还有显著降血脂作用,有效抑制脂肪肝的形成,对糖尿病宠物快速消瘦减肥期的脂肪肝形成具有很好的防治作用。
女贞子提取物:女贞子具有降血糖、降血脂、保肝和调节内分泌功能的作用。女贞子中女贞子素和齐墩果酸均有良好的降血糖作用。齐墩果酸对高脂血症大鼠模型还有很强的降血脂作用,减少脂质异位堆积。女贞子还有减轻肝脏脂肪变性,促进肝细胞再生的作用。女贞子有调节内分泌的水平,女贞子提取物中含有雌、雄激素,能够增加雌、雄激素水平,增加机体的整体代谢水平,促进能量消耗,尤其适合绝育引起的肥胖型糖尿病宠物。女贞子能够充分体现营养代谢性疾病防治“调肝启枢化浊”新理论。女贞子尚含铜、锌、铁、锰等微量元素。
大豆纤维,菊糖,果寡糖:大量多样化的膳食纤维(大豆纤维、菊糖、果寡糖)可通过改善肠道菌群结构来显著改善2型糖尿病人的胰岛素分泌和胰岛素敏感性。
L-肉碱酒石酸盐:是左旋肉碱的稳定形式,而左旋肉碱是人体脂肪代谢过程中的一种必需的辅酶,它作为载体以脂酰肉碱形式将中长链脂肪酸从线粒体膜外转运到膜内,在线粒体的机制内进行β-氧化,从而达到降解脂肪的效果,添加L-肉碱酒石酸盐防止增重,增重可引起胰岛素抵抗。
L-赖氨酸盐酸盐:是赖氨酸的一种存在形式,赖氨酸是动物饲料营养强化剂,可增强食欲,提高抗病能力,保持代谢平衡。
维生素B1:参与机体血糖调控和胰岛素分泌及功能发挥,有助于改善糖耐量。
维生素B12:相关研究证明,补充维生素B12可明显改善糖尿病患者周围神经病变的疼痛。
维生素D3:维生素D3具有改善糖代谢及免疫调节等作用。
维生素E:抗氧化剂维生素E,提高机体的抗高糖应激能力,延缓衰老。
葡萄糖酸锌:锌是胰岛素的重要组成部分,每个胰岛素分子中含有两个锌。当锌缺乏时胰岛素的活性降低,细胞膜结构的稳定性下降,使胰腺细胞溶酶体的外膜破裂造成细胞自溶,便可引起糖尿病。
吡啶甲酸铬:铬元素参与机体血糖调控和胰岛素分泌及功能发挥,有助于改善糖耐量。
本发明的另一方面,提供了一种辅助治疗宠物糖尿病的处方膏的制备方法,所述方法包括:
(1)黄芪提取物、白术提取物、葛根提取物、知母提取物、川芎提取物、桑叶提取物、女贞子提取物、月见草籽油、鱼油、鸡肉粉、牛水解膏、分离乳清蛋白、血红素蛋白粉、大豆纤维、菊糖、果寡糖、L-肉碱酒石酸盐、L-赖氨酸盐酸盐、葡萄糖酸锌、吡啶甲酸铬和苯甲酸钠,按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;将羧甲基纤维素钠按配方比例称量并加入配料罐;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到70-80℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素至配料罐中,继续煮沸20-30分钟。
其中,配料罐为蒸汽加热配料罐。
进一步的,配料罐的蒸汽压控制为0.2-0.4MPa。
更进一步的,配料罐的蒸汽压优选为0.3MPa。
上述制备方法将大部分原料先进行加热搅拌均匀,再将维生素加入进行加热,使得后集中成分不易加热太久被破坏掉,所述制备方法简单,便于操作。
有益效果:本发明的辅助治疗宠物糖尿病的处方膏通过黄芪提取物、白术提取物、葛根提取物、知母提取物、川芎提取物、桑叶提取物、女贞子提取物根据中医中药理论与其它中药配伍,与维生素、L-肉碱酒石酸盐、吡啶甲酸铬等营养素复合,多种成分协同作用,具有降血糖、降血脂、保肝,改善宠物体内糖脂代谢,减少宠物过度肥胖的功能,可辅助治疗宠物糖尿病和预防宠物糖尿病并发症,其制备方法科学合理、简单方便易于操作。
具体实施方式
下面结合实施例对本发明作进一步详细的说明。
实施例1
黄芪提取物:0.5公斤、白术提取物:0.5公斤、葛根提取物:1.5公斤、知母提取物:1公斤、川芎提取物:0.5公斤、桑叶提取物:0.5公斤、女贞子提取物:0.5公斤、羧甲基纤维素钠:0.5公斤、月见草籽油:10公斤、鱼油:2公斤、鸡肉粉:15公斤、牛水解膏:8公斤、分离乳清蛋白:1公斤、血红素蛋白粉:5公斤、大豆纤维:0.5公斤、菊糖:6公斤、果寡糖:1公斤、L-肉碱酒石酸盐:0.2公斤、L-赖氨酸盐酸盐:0.25公斤、维生素B1:0.022公斤、维生素B12:0.005公斤、维生素D3:0.008公斤、维生素E:0.015公斤、葡萄糖酸锌:0.6公斤、吡啶甲酸铬:0.0001公斤、苯甲酸钠:0.25公斤、水:44.6499公斤。
制备方法:
(1)黄芪提取物,白术提取物,葛根提取物,知母提取物,川芎提取物,桑叶提取物,女贞子提取物,月见草籽油,鱼油,鸡肉粉,牛水解膏,分离乳清蛋白,血红素蛋白粉,大豆纤维,菊糖,果寡糖,L-肉碱酒石酸盐,L-赖氨酸盐酸盐,葡萄糖酸锌,吡啶甲酸铬,苯甲酸钠按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;将羧甲基纤维素钠按配方比例称量并加入配料罐;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到70℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素类至配料罐中,继续煮沸20分钟。
其中,配料罐为蒸汽加热配料罐,配料罐的蒸汽压为0.2MPa。
实施例2
黄芪提取物:1公斤、白术提取物:1公斤、葛根提取物:2公斤、知母提取物:1.5公斤、川芎提取物:1公斤、桑叶提取物:1公斤、女贞子提取物:1公斤、羧甲基纤维素钠:0.75公斤、月见草籽油:6公斤、鱼油:6公斤、鸡肉粉:10公斤、牛水解膏:4.5公斤、分离乳清蛋白:2.5公斤、血红素蛋白粉:3公斤、大豆纤维:3.5公斤、菊糖:3公斤、果寡糖:3公斤、L-肉碱酒石酸盐:0.65公斤、L-赖氨酸盐酸盐:0.25公斤、维生素B1:0.022公斤、维生素B12:0.005公斤、维生素D3:0.008公斤、维生素E:0.015公斤、葡萄糖酸锌:0.6公斤、吡啶甲酸铬:0.0001公斤、苯甲酸钠:0.25公斤、水:47.4499公斤。
制备方法:
(1)黄芪提取物,白术提取物,葛根提取物,知母提取物,川芎提取物,桑叶提取物,女贞子提取物,月见草籽油,鱼油,鸡肉粉,牛水解膏,分离乳清蛋白,血红素蛋白粉,大豆纤维,菊糖,果寡糖,L-肉碱酒石酸盐,L-赖氨酸盐酸盐,葡萄糖酸锌,吡啶甲酸铬,苯甲酸钠按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;将羧甲基纤维素钠按配方比例称量并加入配料罐;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到75℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素类至配料罐中,继续煮沸25分钟。
其中,配料罐为蒸汽加热配料罐,配料罐的蒸汽压为0.3MPa。
实施例3
黄芪提取物:1.5公斤,白术提取物:1.5公斤,葛根提取物:2.5公斤,知母提取物:2公斤,川芎提取物:1.5公斤,桑叶提取物:1.5公斤,女贞子:1.5公斤,羧甲基纤维素钠:1公斤,月见草籽油:2公斤,鱼油:10公斤,鸡肉粉:5公斤,牛水解膏:1公斤,分离乳清蛋白:5公斤,血红素蛋白粉:0.5公斤,大豆纤维:6公斤,菊糖:0.5公斤,果寡糖:6公斤,L-肉碱酒石酸盐:1公斤,L-赖氨酸盐酸盐:0.25公斤,维生素B1:0.022公斤,维生素B12:0.005公斤,维生素D3:0.008公斤,维生素E:0.015公斤,葡萄糖酸锌:0.6公斤,吡啶甲酸铬:0.0001公斤,苯甲酸钠:0.25公斤,水:48.8499公斤。
制备方法:
(1)黄芪提取物,白术提取物,葛根提取物,知母提取物,川芎提取物,桑叶提取物,女贞子提取物,月见草籽油,鱼油,鸡肉粉,牛水解膏,分离乳清蛋白,血红素蛋白粉,大豆纤维,菊糖,果寡糖,L-肉碱酒石酸盐,L-赖氨酸盐酸盐,葡萄糖酸锌,吡啶甲酸铬,苯甲酸钠按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;将羧甲基纤维素钠按配方比例称量并加入配料罐;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到80℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素类至配料罐中,继续煮沸30分钟。
其中,配料罐为蒸汽加热配料罐,配料罐的蒸汽压为0.4MPa。
辅助治疗宠物糖尿病的处方膏有效性试验
辅助治疗宠物糖尿病的处方膏用于宠物在患有糖尿病期间的营养护理和辅助改善糖脂代谢,预防并发症作用的功能用营养品。本试验根据自主设计评估指标,选取成年大鼠作为试验研究对象,比较分析辅助治疗宠物糖尿病的处方膏在临床上是否具有辅助降血糖的功效,从而判断其能否对糖尿病动物发挥相关功能保健作用。
1试验动物:选用健康成年大鼠,大鼠体重160-200g,雄性,大鼠每组10只。
2供试样品:分别按照本发明的实施例1、实施例2和实施例3中的原料配方及其制备方法进行制作,形成三种食用液体膏体备用。
3试验方法
3.1正常动物降糖试验:将雄性大鼠,按禁食3-5小时后的血糖水平分组,随机选1个对照组和3个应用例组。对照组给予溶剂(蒸馏水),3个应用例组分别给予对应的供试样品,即:应用例1组给予按本发明实施例1的配方制作的食用液体膏体,应用例2组给予按本发明实施例2的配方制作的食用液体膏体,应用例3组给予按本发明实施例3的配方制作的食用液体膏体,连续30天,测空腹血糖值(禁食同试验前),比较各组动物血糖值。
3.2高血糖模型降糖试验
3.2.1造模:胰岛损伤高血糖模型,将另购入的一批健康雄性大鼠,禁食3-5小时,测空腹血糖,作为该批次大鼠基础血糖值。随后大鼠禁食24小时(自由饮水),注射四氧嘧啶(用前新鲜配制,120mg/kg BW.ip)造模,5-7天后大鼠禁食3-5小时,测血糖,血糖值10-25mmol/L为高血糖模型成功大鼠。
3.2.2高血糖模型动物降糖试验:选造模成功的高血糖模型大鼠按禁食3-5小时的血糖水平分组,随机选1个模型对照组和3个应用例组。模型对照组给予溶剂(蒸馏水),应用例组分别给予对应供试样品,即:应用例1组给予按本发明实施例1的配方制作的食用液体膏体,应用例2组给予按本发明实施例2的配方制作的食用液体膏体,应用例3组给予按本发明实施例3的配方制作的食用液体膏体,连续30天,测空腹血糖值(禁食同试验前),比较各组动物血糖值及血糖下降百分率。
4数据处理:试验数据先进行方差齐性检验,方差齐,用SPSS20.0统计软件进行方差分析。
5结果
5.1正常动物降糖试验结果
与对照组比较,各应用例组的空腹血糖指标,无显著性差异(方差齐,p>0.05),即无统计学意义,详见表1。提示3个应用例组对正常大鼠血糖均无影响。
表1正常动物各组的空腹血糖指标(n=10,)
注:*表示p<0.05,**表示p<0.01,无标记*表示p>0.05。
5.2高血糖模型降糖试验结果
与模型对照组比较,各应用例组的空腹血糖显著性下降(方差齐,p<0.05或0.01),血糖下降百分率显著性升高(方差齐,p<0.05或0.01);其中应用例2组的空腹血糖、血糖下降百分率具有极为显著性差异(方差齐,p<0.01);详见表2。提示3个应用例组的空腹血糖及血糖下降百分率指标结果均呈阳性。
表2各模型组空腹血糖及血糖下降百分率指标(n=10,)
注:*表示p<0.05,**表示p<0.01。
6结论
综上所述,本发明的辅助治疗宠物糖尿病的处方膏对正常大鼠空腹血糖均无不良影响;对高血糖模型大鼠的空腹血糖、血糖下降百分率指标均呈阳性;由此可判定本发明的辅助治疗宠物糖尿病的处方膏具有一定的辅助降血糖功能,可辅助治疗宠物糖尿病和预防宠物糖尿病并发症。其中,在高血糖模型降糖试验中应用例2组对空腹血糖、血糖下降百分率显著性差异最为明显,其所对应的实施例2为本发明的最佳实施例。
以上仅是本发明的一些实施方式,对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。
Claims (9)
1.辅助治疗宠物糖尿病的处方膏,其特征在于:包括以下原料组分:黄芪提取物、白术提取物、葛根提取物、知母提取物、川芎提取物、桑叶提取物、女贞子提取物、羧甲基纤维素钠、月见草籽油、鱼油、鸡肉粉、牛水解膏、分离乳清蛋白、血红素蛋白粉、大豆纤维、菊糖、果寡糖、L-肉碱酒石酸盐、L-赖氨酸盐酸盐、葡萄糖酸锌、吡啶甲酸铬和苯甲酸钠。
2.根据权利要求1所述的辅助治疗宠物糖尿病的处方膏,其特征在于:还包括维生素。
3.根据权利要求2所述的辅助治疗宠物糖尿病的处方膏,其特征在于:所述维生素包括维生素B1、维生素B12、维生素D3和维生素E中的一种或多种。
4.根据权利要求3所述的辅助治疗宠物糖尿病的处方膏,其特征在于:包括以下质量百分数含量的原料组分:黄芪提取物:0.5%-1.5%、白术提取物:0.5%-1.5%、葛根提取物:1.5%-2.5%、知母提取物:1%-2%、川芎提取物:0.5%-1.5%、桑叶提取物:0.5%-1.5%、女贞子提取物:0.5%-1.5%、羧甲基纤维素钠:0.5%-1%、月见草籽油:2%-10%、鱼油:2%-10%、鸡肉粉:5%-15%、牛水解膏:1%-8%、分离乳清蛋白:1%-5%、血红素蛋白粉:0.5%-5%、大豆纤维:0.5%-6%、菊糖:0.5%-6%、果寡糖:1%-6%、L-肉碱酒石酸盐:0.2%-1%、L-赖氨酸盐酸盐:0.25%、维生素B1:0.022%、维生素B12:0.005%、维生素D3:0.008%、维生素E:0.015%、葡萄糖酸锌:0.6%、吡啶甲酸铬:0.0001%、苯甲酸钠:0.25%,余量由水补足。
5.根据权利要求4所述的辅助治疗宠物糖尿病的处方膏,其特征在于:优选原料配方及其质量百分数含量为:黄芪提取物:1%、白术提取物:1%、葛根提取物:2%、知母提取物:1.5%、川芎提取物:1%、桑叶提取物:1%、女贞子提取物:1%、羧甲基纤维素钠:0.75%、月见草籽油:6%、鱼油:6%、鸡肉粉:10%、牛水解膏:4.5%、分离乳清蛋白:2.5%、血红素蛋白粉:3%、大豆纤维:3.5%、菊糖:3%、果寡糖:3%、L-肉碱酒石酸盐:0.65%和L-赖氨酸盐酸盐:0.25%。
6.一种如权利要求1-5任一项所述的辅助治疗宠物糖尿病的处方膏的制备方法,其特征在于:所述方法包括:
(1)黄芪提取物、白术提取物、葛根提取物、知母提取物、川芎提取物、桑叶提取物、女贞子提取物、月见草籽油、鱼油、鸡肉粉、牛水解膏、分离乳清蛋白、血红素蛋白粉、大豆纤维、菊糖、果寡糖、L-肉碱酒石酸盐、L-赖氨酸盐酸盐、葡萄糖酸锌、吡啶甲酸铬和苯甲酸钠,按配方比例称量投入配料罐内,按配方比例加入水均质搅拌成浆;将羧甲基纤维素钠按配方比例称量并加入配料罐;
(2)开启配料罐的进汽开关,将步骤(1)所得产物边搅拌边加热到70-80℃时;
(3)将步骤(2)所得产物搅拌煮沸后依次加入按配方比例称量所得的维生素至配料罐中,继续煮沸20-30分钟。
7.根据权利要求6所述的辅助治疗宠物糖尿病的处方膏的制备方法,其特征在于:所述配料罐为蒸汽加热配料罐。
8.根据权利要求7所述的辅助治疗宠物糖尿病的处方膏的制备方法,其特征在于:所述配料罐的蒸汽压控制为0.2-0.4MPa。
9.根据权利要求8所述的辅助治疗宠物糖尿病的处方膏的制备方法,其特征在于:所述配料罐的蒸汽压优选为0.3MPa。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811107961.7A CN109331113A (zh) | 2018-09-21 | 2018-09-21 | 辅助治疗宠物糖尿病的处方膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811107961.7A CN109331113A (zh) | 2018-09-21 | 2018-09-21 | 辅助治疗宠物糖尿病的处方膏及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109331113A true CN109331113A (zh) | 2019-02-15 |
Family
ID=65306373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811107961.7A Pending CN109331113A (zh) | 2018-09-21 | 2018-09-21 | 辅助治疗宠物糖尿病的处方膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109331113A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11896581B2 (en) | 2020-09-04 | 2024-02-13 | Société des Produits Nestlé S.A. | Compositions and methods for providing health benefits in an animal |
EP4353088A1 (en) * | 2022-10-14 | 2024-04-17 | Servicio Andaluz de Salud | Compositions or combined preparations of essential oils and l-carnitine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813910A (zh) * | 2005-02-05 | 2006-08-09 | 北京北大维信生物科技有限公司 | 一种具有降糖作用的药物组合物及其制备方法 |
CN1947778A (zh) * | 2006-11-10 | 2007-04-18 | 北京百世利康医药科技有限公司 | 一种具有降血糖作用的药物制剂及其制备方法 |
CN104543834A (zh) * | 2014-12-30 | 2015-04-29 | 山东龙力生物科技股份有限公司 | 一种具有降血糖功效的南瓜粉及其制备方法 |
CN107691838A (zh) * | 2017-09-20 | 2018-02-16 | 深圳市红瑞生物科技有限公司 | 宠物绝育缓释膏及其制备方法 |
-
2018
- 2018-09-21 CN CN201811107961.7A patent/CN109331113A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813910A (zh) * | 2005-02-05 | 2006-08-09 | 北京北大维信生物科技有限公司 | 一种具有降糖作用的药物组合物及其制备方法 |
CN1947778A (zh) * | 2006-11-10 | 2007-04-18 | 北京百世利康医药科技有限公司 | 一种具有降血糖作用的药物制剂及其制备方法 |
CN104543834A (zh) * | 2014-12-30 | 2015-04-29 | 山东龙力生物科技股份有限公司 | 一种具有降血糖功效的南瓜粉及其制备方法 |
CN107691838A (zh) * | 2017-09-20 | 2018-02-16 | 深圳市红瑞生物科技有限公司 | 宠物绝育缓释膏及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11896581B2 (en) | 2020-09-04 | 2024-02-13 | Société des Produits Nestlé S.A. | Compositions and methods for providing health benefits in an animal |
EP4353088A1 (en) * | 2022-10-14 | 2024-04-17 | Servicio Andaluz de Salud | Compositions or combined preparations of essential oils and l-carnitine |
WO2024079360A1 (en) * | 2022-10-14 | 2024-04-18 | Servicio Andaluz De Salud | Compositions or combined preparations of essential oils and l-carnitine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101878790B (zh) | 一种糖尿病专用强化营养面粉及其制备方法 | |
CN102919836B (zh) | 一种降糖、降压、降脂、通便养颜、减肥、抗疲劳保健品及其生产工艺 | |
CN102907604B (zh) | 一种降糖、降压、减肥、通便养颜、抗疲劳保健品及其生产工艺 | |
CN102429066B (zh) | 一种能够增强体力抗疲劳的复方玛咖咖啡制品 | |
CN105795468A (zh) | 一种具有减肥功效的组合物 | |
CA2517172C (en) | Therapeutic compositions | |
CN101473953A (zh) | 净血排毒组合食品及其加工方法和应用 | |
MXPA04006166A (es) | Composiciones que incorporan al acido (-)-hidroxicitrico. al cromo y al acido gimnemico y metodos relacionados para promover un peso corporal adecuado y mejorar los factores relacionados con la salud. | |
CN109745359A (zh) | 有利于保持血糖平衡和预防糖尿病及其并发症的组合物及其制备方法 | |
CN108703364A (zh) | 脂肪酸代谢异常专用型临床营养配方及其制备方法 | |
CN101208080A (zh) | 用于治疗葡萄糖代谢受损的药物 | |
CN102613453B (zh) | 一种用于糖尿病患者的海洋生物型肠内营养制剂及其制备方法和用途 | |
CN109331113A (zh) | 辅助治疗宠物糖尿病的处方膏及其制备方法 | |
CN100518733C (zh) | 用于治疗和预防糖尿病的组合物 | |
CN102231986B (zh) | 植物蜕皮激素在制备对代谢综合征有效的组合物中的用途 | |
CN102526479A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
JP6445686B2 (ja) | ジペノサイド75の抗糖尿病効果 | |
CN101224202A (zh) | 减肥组合物 | |
CN102847159A (zh) | 一种葡萄糖新陈代谢增强剂 | |
CN107223981B (zh) | 含大豆多肽阿格拉欣的组合物及其制备方法 | |
CN105707681A (zh) | 一种具有降血糖功能的超微黑木耳粉营养粥及其制备方法 | |
CN1927223A (zh) | 减肥养颜胶囊 | |
CN102090453A (zh) | 瘦身美奶茶 | |
CN102552574A (zh) | 一种减肥功能的保健药物配方 | |
Lim et al. | Anti-diabetic effect of material fermented using rice bran and soybean as the main ingredient by Bacillus sp. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190215 |